Literature DB >> 15805049

Idiosyncratic liver injury: challenges and approaches.

Paul B Watkins1.   

Abstract

Clinical presentations of drug-induced liver injury (DILI) cover essentially the entire spectrum of known liver diseases. However, in the last 8 years the form of liver injury that has most frequently resulted in labeling restrictions is idiosyncratic hepatocellular injury leading to acute liver failure. This rare form of DILI has a characteristic clinical presentation that includes an acute onset after uneventful treatment with drug for weeks to months. Serum alanine aminotransferase rises to very high levels and the appearance of jaundice indicates a high mortality even if the therapy is discontinued. Drugs that can cause this type of injury almost always are associated with frequent (2-15% of all treated patients) and minor serum aminotransferase elevations. These elevations are believed to reflect true liver injury, but often reverse even if drug therapy is continued. The bases for this "adaptation" is not known, as is why some patients do not adapt and develop progressive liver injury. Understanding how drugs cause severe idiosyncratic hepatocellular toxicity has been frustrated by the lack of good preclinical models. Indeed, because these events occur so rarely, the vast majority of humans are not good models. Studies of genomic DNA from affected individuals should provide important insight but not the complete answer because environmental factors almost certainly contribute to individual susceptibility. The most fruitful approach may therefore lie in focused and well-controlled phenotype/genotype studies of the rare patients who have survived this type of injury. The National Institute of Diabetes and Digestive and Kidney Diseases of The National Institutes of Health has recently sponsored a cooperative agreement (UO1) to create a Drug Induced Liver Injury Network (DILIN). DILIN consists of University of Michigan, Indiana University, University of Connecticut, University of California, San Francisco, University of North Carolina, and Duke University. This network should provide heretofore missing resources required to address the problem.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15805049     DOI: 10.1080/01926230590888306

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  39 in total

Review 1.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2010-06-10       Impact factor: 4.849

Review 2.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Authors:  Russell A Wilke; Debbie W Lin; Dan M Roden; Paul B Watkins; David Flockhart; Issam Zineh; Kathleen M Giacomini; Ronald M Krauss
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

Review 3.  Drug-induced liver injury: review article.

Authors:  Wissam Bleibel; Stephen Kim; Karl D'Silva; Eric R Lemmer
Journal:  Dig Dis Sci       Date:  2007-03-16       Impact factor: 3.199

Review 4.  Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications.

Authors:  Lily Dara; Zhang-Xu Liu; Neil Kaplowitz
Journal:  Liver Int       Date:  2015-11-11       Impact factor: 5.828

5.  Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.

Authors:  Ayako Suzuki; Raul J Andrade; Einar Bjornsson; M Isabel Lucena; William M Lee; Nancy A Yuen; Christine M Hunt; James W Freston
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

6.  D-penicillamine-induced granulomatous hepatitis in brown Norway rats.

Authors:  Imir G Metushi; Xu Zhu; Jack Uetrecht
Journal:  Mol Cell Biochem       Date:  2014-04-27       Impact factor: 3.396

7.  Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase.

Authors:  Kyle L Poulsen; Ryan P Albee; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2014-02-13       Impact factor: 4.030

Review 8.  Emerging treatments for post-transplantation diabetes mellitus.

Authors:  Trond Jenssen; Anders Hartmann
Journal:  Nat Rev Nephrol       Date:  2015-04-28       Impact factor: 28.314

9.  Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction.

Authors:  Kevin M Beggs; Aaron M Fullerton; Kazuhisa Miyakawa; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2013-10-04       Impact factor: 4.849

Review 10.  Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria.

Authors:  Derick Han; Lily Dara; Sanda Win; Tin Aung Than; Liyun Yuan; Sadeea Q Abbasi; Zhang-Xu Liu; Neil Kaplowitz
Journal:  Trends Pharmacol Sci       Date:  2013-02-28       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.